Results 81 to 90 of about 23,850 (163)

Pioglitazone: Indian perspective

Indian Journal of Endocrinology and Metabolism, 2011
Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance.
Rishi Shukla, Sanjay Kalra
doaj  

Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines, Pietro Salvago, Francesca Vaccaro, Davide Vaccaro, Ginevra Malta, Fabiana Plescia, Stella Cascioferro, Gianluca Lavanco, Fulvio Plescia   +8 more
wiley   +1 more source

A Path‐Based Approach for Detecting and Assessing Inconsistency in Network Meta‐Analysis

Statistics in Medicine, Volume 45, Issue 23-24, October 2026.
ABSTRACT Network Meta‐Analysis (NMA) is a statistical technique for synthesizing evidence from various sources to compare multiple interventions. NMA relies on integrating both direct evidence from head‐to‐head comparisons and indirect evidence from different paths that link treatments through common comparators.
Noosheen R. Tahmasebi, Annabel L. Davies, Theodoros Papakonstantinou, Gerta Rücker, Adriani Nikolakopoulou   +4 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Risk management in the treatment of type 2 diabetes with pioglitazone

Diabetes, Metabolic Syndrome and Obesity, 2009
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors.
Giuseppe Derosa, Sibilla AT Salvadeo
doaj  

Transcriptomic and metabolomic analyses reveal that lobeglitazone ameliorates hepatic steatosis in rats concurrent with regulation of mitochondrial pyruvate metabolism

British Journal of Pharmacology, Volume 183, Issue 19, Page 5935-5952, October 2026.
Background and Purpose Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2 diabetes mellitus.
Hyekyung Yang, Su Young Son, Youngmi Song, Hyewon Choi, In‐Gu Do, Choong Hwan Lee, Cheol‐Young Park   +6 more
wiley   +1 more source

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin

Diabetes, Metabolic Syndrome and Obesity, 2014
Masahiro Ohira,1 Takashi Yamaguchi,1 Atsuhito Saiki,1 Noriko Ban,1 Hidetoshi Kawana,1 Ayako Nagumo,1 Takeyoshi Murano,2 Kohji Shirai,3 Ichiro Tatsuno1 1Center for Diabetes, Endocrinology and Metabolism, 2Department of Clinical Laboratory Medicine ...
Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagumo A, Murano T, Shirai K, Tatsuno I   +8 more
doaj  

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Pioglitazone significantly reduces the risk of stroke in people with diabetes, and in those with prediabetes, it markedly reduces the risk of stroke/myocardial infarction and new‐onset diabetes.
Fei Yuan, J. David Spence, Jean‐Eric Tarride   +2 more
doaj   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source